Cancer pharmacology and pharmacotherapy review :: study guide for oncology boards and MOC exams /
Cancer Pharmacology and Pharmacotherapy Review is the first book devoted entirely to providing the 'must-know' facts on each cancer agent including their pharmacokinetics, FDA-approved indications, toxicity, interactions, and other important information that is commonly found on board exam...
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
New York :
Demos Medical,
[2016]
|
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Zusammenfassung: | Cancer Pharmacology and Pharmacotherapy Review is the first book devoted entirely to providing the 'must-know' facts on each cancer agent including their pharmacokinetics, FDA-approved indications, toxicity, interactions, and other important information that is commonly found on board examinations and essential for any clinician or practitioner to review . The authors, an oncologist and two pharmacists, have developed a handy question-and-answer format to present the material in digestible bursts. As the pharmacology section continues to represent a major portion of the medical oncology exam and a key component on oncology MOC exams, this portable study guide will help prepare anyone looking to fine-tune their knowledge on cancer drugs before the test. Not to mention, with recent advancements in the field of cancer treatment, it has become more cumbersome to recall and maintain essential knowledge of every cancer therapeuticómaking this book not only an exam resource but also a handy quick reference for oncologists and pharmacists alike. Key Features: Conveniently organized and arranged by drug class and subtypes for easier recall and classification Includes proper dosage adjustments to account for liver and kidney dysfunction. Features tables throughout that provide quick reference regarding FDA-approved medications Simplified diagrams and illustrations facilitate the pharmacokinetic processes. |
| Beschreibung: | Includes index. |
| Beschreibung: | 1 online resource (xiv, 189 pages) : color illustrations |
| ISBN: | 9781617052521 1617052523 162070076X 9781620700761 |
Internformat
MARC
| LEADER | 00000cam a2200000 i 4500 | ||
|---|---|---|---|
| 001 | ZDB-4-EBA-ocn942588609 | ||
| 003 | OCoLC | ||
| 005 | 20241004212047.0 | ||
| 006 | m o d | ||
| 007 | cr cnu|||unuuu | ||
| 008 | 160302s2016 nyua o 001 0 eng d | ||
| 040 | |a N$T |b eng |e rda |e pn |c N$T |d IDEBK |d YDXCP |d N$T |d OCLCQ |d CDX |d OCLCF |d EBLCP |d USU |d OCLCQ |d VT2 |d OCLCO |d OCLCQ |d OCLCO |d OCLCL | ||
| 066 | |c (S | ||
| 019 | |a 946309732 |a 1235840107 | ||
| 020 | |a 9781617052521 |q (electronic bk.) | ||
| 020 | |a 1617052523 |q (electronic bk.) | ||
| 020 | |z 9781620700761 | ||
| 020 | |a 162070076X | ||
| 020 | |a 9781620700761 | ||
| 035 | |a (OCoLC)942588609 |z (OCoLC)946309732 |z (OCoLC)1235840107 | ||
| 050 | 4 | |a RS431.A64 | |
| 060 | 4 | |a QV 18.2 | |
| 072 | 7 | |a MED |x 071000 |2 bisacsh | |
| 082 | 7 | |a 615.7/98076 |2 23 | |
| 049 | |a MAIN | ||
| 100 | 1 | |a Worden, Francis P., |e author. |0 http://id.loc.gov/authorities/names/n2013181342 | |
| 245 | 1 | 0 | |a Cancer pharmacology and pharmacotherapy review : |b study guide for oncology boards and MOC exams / |c Francis P. Worden, Anthony J. Perissinotti, Bernard L. Marini. |
| 264 | 1 | |a New York : |b Demos Medical, |c [2016] | |
| 300 | |a 1 online resource (xiv, 189 pages) : |b color illustrations | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 588 | 0 | |a Online resource; title from PDF title page (EBSCO, viewed March 8, 2016). | |
| 500 | |a Includes index. | ||
| 520 | |a Cancer Pharmacology and Pharmacotherapy Review is the first book devoted entirely to providing the 'must-know' facts on each cancer agent including their pharmacokinetics, FDA-approved indications, toxicity, interactions, and other important information that is commonly found on board examinations and essential for any clinician or practitioner to review . The authors, an oncologist and two pharmacists, have developed a handy question-and-answer format to present the material in digestible bursts. As the pharmacology section continues to represent a major portion of the medical oncology exam and a key component on oncology MOC exams, this portable study guide will help prepare anyone looking to fine-tune their knowledge on cancer drugs before the test. Not to mention, with recent advancements in the field of cancer treatment, it has become more cumbersome to recall and maintain essential knowledge of every cancer therapeuticómaking this book not only an exam resource but also a handy quick reference for oncologists and pharmacists alike. Key Features: Conveniently organized and arranged by drug class and subtypes for easier recall and classification Includes proper dosage adjustments to account for liver and kidney dysfunction. Features tables throughout that provide quick reference regarding FDA-approved medications Simplified diagrams and illustrations facilitate the pharmacokinetic processes. | ||
| 505 | 0 | |a Cover; Title; Copyright; Contents; List of Figures; List of Tables; Preface; Share Cancer Pharmacology and Pharmacotherapy Review: Study Guide for Oncology Boards and MOC Exams; Part I: Traditional Chemotherapy; Chapter 1: Microtubule Inhibitors; Taxanes and Related Agents; Vinca Alkaloids; Chapter 2: Alkylating Agents; Nitrogen Mustards; Non-Nitrogen Mustards; Platinums; Antitumor Antibiotics; Chapter 3: Enzyme Inhibitors-Topoisomerase I Inhibitors; Camptothecans; Chapter 4: Enzyme Inhibitors-Topoisomerase II Inhibitors; Epipodophyllotoxins; Anthracyclines; Chapter 5: Antimetabolites | |
| 505 | 8 | |a AntifolatesPurine Antagonists; Purine Analogues; Pyrimidine Analogues/Fluoropyrimidines; Pyrimidine Analogues/Deoxycytidine Analogues; Part II: Next-Generation Antineoplastics; Chapter 6: Monoclonal Antibodies; Chapter 7: VEGF Trap; Ziv-Aflibercept (Zaltrap®); Chapter 8: Tyrosine Kinase Inhibitors; Angiogenesis Inhibitors and Multi-Kinase Inhibitors; Breakpoint Cluster Region-Abelson Murine Leukemia Viral Oncogene Homolog 1 (BCR-ABL) Inhibitors; B-Cell Receptor (BCR) Pathway Inhibitors; EGFR-Ras-Raf-MEK-ERK (MAPK) Pathway Inhibitors; Miscellaneous Oral Targeted Therapies | |
| 505 | 8 | |6 880-01 |a Appendix A: Agents Requiring Renal and/or Hepatic Dose AdjustmentsAppendix B: Extravasation Risk of Chemotherapeutic Agents; Index | |
| 650 | 0 | |a Antineoplastic agents |x Physiological effect |v Problems, exercises, etc. | |
| 650 | 0 | |a Tumors |x Chemotherapy |v Problems, exercises, etc. | |
| 650 | 2 | |a Antineoplastic Agents |x pharmacology |0 https://id.nlm.nih.gov/mesh/D000970Q000494 | |
| 650 | 2 | |a Neoplasms |x drug therapy |0 https://id.nlm.nih.gov/mesh/D009369Q000188 | |
| 650 | 6 | |a Anticancéreux |x Effets physiologiques |v Problèmes et exercices. | |
| 650 | 6 | |a Tumeurs |x Chimiothérapie |v Problèmes et exercices. | |
| 650 | 7 | |a MEDICAL |x Pharmacology. |2 bisacsh | |
| 650 | 7 | |a Antineoplastic agents |x Physiological effect |2 fast | |
| 650 | 7 | |a Tumors |x Chemotherapy |2 fast | |
| 655 | 2 | |a Examination Questions |0 https://id.nlm.nih.gov/mesh/D020475 | |
| 655 | 2 | |a Problems and Exercises |0 https://id.nlm.nih.gov/mesh/D020497 | |
| 655 | 7 | |a exercise books. |2 aat | |
| 655 | 7 | |a Problems and exercises |2 fast | |
| 655 | 7 | |a Problems and exercises. |2 lcgft |0 http://id.loc.gov/authorities/genreForms/gf2014026154 | |
| 655 | 7 | |a Problèmes et exercices. |2 rvmgf | |
| 700 | 1 | |a Perissinotti, Anthony J., |e author. |0 http://id.loc.gov/authorities/names/n2015190361 | |
| 700 | 1 | |a Marini, Bernard L., |e author. |0 http://id.loc.gov/authorities/names/n2015190362 | |
| 758 | |i has work: |a Cancer pharmacology and pharmacotherapy review (Text) |1 https://id.oclc.org/worldcat/entity/E39PCGCPrkhPt7kvqgxrr7VJMq |4 https://id.oclc.org/worldcat/ontology/hasWork | ||
| 776 | 0 | 8 | |i Print version: |a Worden, Francis P., MD. |t Cancer Pharmacology and Pharmacotherapy Review : Study Guide for Oncology Boards and MOC Exams. |d : Springer Publishing Company, ©2016 |z 9781620700761 |w (DLC) 2015045238 |w (OCoLC)930576198 |
| 856 | 4 | 0 | |l FWS01 |p ZDB-4-EBA |q FWS_PDA_EBA |u https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=1193410 |3 Volltext |
| 880 | 8 | |6 505-01/(S |a Chapter 9: Antiandrogen TherapiesChapter 10: Mammalian Target of Rapamycin (mTOR) Inhibitors; Chapter 11: Histone Deacetylase (HDAC) Inhibitors; Chapter 12: Hypomethylating Agents; Chapter 13: Proteasome Inhibitors; Chapter 14: Immunomodulatory Agents; Chapter 15: L-Asparaginase Enzymes; Chapter 16: Promyelocytic Leukemia Gene Retinoic Acid Receptor-Alpha (PML-RARα) Translocation Inhibitors; Part III: Miscellaneous Oncolytics; Chapter 17: Sipuleucel-T (Provenge®); Chapter 18: Omacetaxine (Synribo®); Chapter 19: Estramustine (Emcyt®) | |
| 938 | |a EBSCOhost |b EBSC |n 1193410 | ||
| 938 | |a ProQuest MyiLibrary Digital eBook Collection |b IDEB |n cis34101607 | ||
| 938 | |a YBP Library Services |b YANK |n 12872620 | ||
| 938 | |a Coutts Information Services |b COUT |n 34101607 | ||
| 938 | |a ProQuest Ebook Central |b EBLB |n EBL4428049 | ||
| 994 | |a 92 |b GEBAY | ||
| 912 | |a ZDB-4-EBA | ||
| 049 | |a DE-863 | ||
Datensatz im Suchindex
| DE-BY-FWS_katkey | ZDB-4-EBA-ocn942588609 |
|---|---|
| _version_ | 1816882341057921024 |
| adam_text | |
| any_adam_object | |
| author | Worden, Francis P. Perissinotti, Anthony J. Marini, Bernard L. |
| author_GND | http://id.loc.gov/authorities/names/n2013181342 http://id.loc.gov/authorities/names/n2015190361 http://id.loc.gov/authorities/names/n2015190362 |
| author_facet | Worden, Francis P. Perissinotti, Anthony J. Marini, Bernard L. |
| author_role | aut aut aut |
| author_sort | Worden, Francis P. |
| author_variant | f p w fp fpw a j p aj ajp b l m bl blm |
| building | Verbundindex |
| bvnumber | localFWS |
| callnumber-first | R - Medicine |
| callnumber-label | RS431 |
| callnumber-raw | RS431.A64 |
| callnumber-search | RS431.A64 |
| callnumber-sort | RS 3431 A64 |
| callnumber-subject | RS - Pharmacy |
| collection | ZDB-4-EBA |
| contents | Cover; Title; Copyright; Contents; List of Figures; List of Tables; Preface; Share Cancer Pharmacology and Pharmacotherapy Review: Study Guide for Oncology Boards and MOC Exams; Part I: Traditional Chemotherapy; Chapter 1: Microtubule Inhibitors; Taxanes and Related Agents; Vinca Alkaloids; Chapter 2: Alkylating Agents; Nitrogen Mustards; Non-Nitrogen Mustards; Platinums; Antitumor Antibiotics; Chapter 3: Enzyme Inhibitors-Topoisomerase I Inhibitors; Camptothecans; Chapter 4: Enzyme Inhibitors-Topoisomerase II Inhibitors; Epipodophyllotoxins; Anthracyclines; Chapter 5: Antimetabolites AntifolatesPurine Antagonists; Purine Analogues; Pyrimidine Analogues/Fluoropyrimidines; Pyrimidine Analogues/Deoxycytidine Analogues; Part II: Next-Generation Antineoplastics; Chapter 6: Monoclonal Antibodies; Chapter 7: VEGF Trap; Ziv-Aflibercept (Zaltrap®); Chapter 8: Tyrosine Kinase Inhibitors; Angiogenesis Inhibitors and Multi-Kinase Inhibitors; Breakpoint Cluster Region-Abelson Murine Leukemia Viral Oncogene Homolog 1 (BCR-ABL) Inhibitors; B-Cell Receptor (BCR) Pathway Inhibitors; EGFR-Ras-Raf-MEK-ERK (MAPK) Pathway Inhibitors; Miscellaneous Oral Targeted Therapies Appendix A: Agents Requiring Renal and/or Hepatic Dose AdjustmentsAppendix B: Extravasation Risk of Chemotherapeutic Agents; Index |
| ctrlnum | (OCoLC)942588609 |
| dewey-full | 615.7/98076 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 615 - Pharmacology and therapeutics |
| dewey-raw | 615.7/98076 |
| dewey-search | 615.7/98076 |
| dewey-sort | 3615.7 598076 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>06862cam a2200745 i 4500</leader><controlfield tag="001">ZDB-4-EBA-ocn942588609</controlfield><controlfield tag="003">OCoLC</controlfield><controlfield tag="005">20241004212047.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr cnu|||unuuu</controlfield><controlfield tag="008">160302s2016 nyua o 001 0 eng d</controlfield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">N$T</subfield><subfield code="b">eng</subfield><subfield code="e">rda</subfield><subfield code="e">pn</subfield><subfield code="c">N$T</subfield><subfield code="d">IDEBK</subfield><subfield code="d">YDXCP</subfield><subfield code="d">N$T</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">CDX</subfield><subfield code="d">OCLCF</subfield><subfield code="d">EBLCP</subfield><subfield code="d">USU</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">VT2</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCL</subfield></datafield><datafield tag="066" ind1=" " ind2=" "><subfield code="c">(S</subfield></datafield><datafield tag="019" ind1=" " ind2=" "><subfield code="a">946309732</subfield><subfield code="a">1235840107</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781617052521</subfield><subfield code="q">(electronic bk.)</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1617052523</subfield><subfield code="q">(electronic bk.)</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="z">9781620700761</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">162070076X</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781620700761</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)942588609</subfield><subfield code="z">(OCoLC)946309732</subfield><subfield code="z">(OCoLC)1235840107</subfield></datafield><datafield tag="050" ind1=" " ind2="4"><subfield code="a">RS431.A64</subfield></datafield><datafield tag="060" ind1=" " ind2="4"><subfield code="a">QV 18.2</subfield></datafield><datafield tag="072" ind1=" " ind2="7"><subfield code="a">MED</subfield><subfield code="x">071000</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="082" ind1="7" ind2=" "><subfield code="a">615.7/98076</subfield><subfield code="2">23</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">MAIN</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Worden, Francis P.,</subfield><subfield code="e">author.</subfield><subfield code="0">http://id.loc.gov/authorities/names/n2013181342</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Cancer pharmacology and pharmacotherapy review :</subfield><subfield code="b">study guide for oncology boards and MOC exams /</subfield><subfield code="c">Francis P. Worden, Anthony J. Perissinotti, Bernard L. Marini.</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">New York :</subfield><subfield code="b">Demos Medical,</subfield><subfield code="c">[2016]</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource (xiv, 189 pages) :</subfield><subfield code="b">color illustrations</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="588" ind1="0" ind2=" "><subfield code="a">Online resource; title from PDF title page (EBSCO, viewed March 8, 2016).</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Includes index.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Cancer Pharmacology and Pharmacotherapy Review is the first book devoted entirely to providing the 'must-know' facts on each cancer agent including their pharmacokinetics, FDA-approved indications, toxicity, interactions, and other important information that is commonly found on board examinations and essential for any clinician or practitioner to review . The authors, an oncologist and two pharmacists, have developed a handy question-and-answer format to present the material in digestible bursts. As the pharmacology section continues to represent a major portion of the medical oncology exam and a key component on oncology MOC exams, this portable study guide will help prepare anyone looking to fine-tune their knowledge on cancer drugs before the test. Not to mention, with recent advancements in the field of cancer treatment, it has become more cumbersome to recall and maintain essential knowledge of every cancer therapeuticómaking this book not only an exam resource but also a handy quick reference for oncologists and pharmacists alike. Key Features: Conveniently organized and arranged by drug class and subtypes for easier recall and classification Includes proper dosage adjustments to account for liver and kidney dysfunction. Features tables throughout that provide quick reference regarding FDA-approved medications Simplified diagrams and illustrations facilitate the pharmacokinetic processes.</subfield></datafield><datafield tag="505" ind1="0" ind2=" "><subfield code="a">Cover; Title; Copyright; Contents; List of Figures; List of Tables; Preface; Share Cancer Pharmacology and Pharmacotherapy Review: Study Guide for Oncology Boards and MOC Exams; Part I: Traditional Chemotherapy; Chapter 1: Microtubule Inhibitors; Taxanes and Related Agents; Vinca Alkaloids; Chapter 2: Alkylating Agents; Nitrogen Mustards; Non-Nitrogen Mustards; Platinums; Antitumor Antibiotics; Chapter 3: Enzyme Inhibitors-Topoisomerase I Inhibitors; Camptothecans; Chapter 4: Enzyme Inhibitors-Topoisomerase II Inhibitors; Epipodophyllotoxins; Anthracyclines; Chapter 5: Antimetabolites</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">AntifolatesPurine Antagonists; Purine Analogues; Pyrimidine Analogues/Fluoropyrimidines; Pyrimidine Analogues/Deoxycytidine Analogues; Part II: Next-Generation Antineoplastics; Chapter 6: Monoclonal Antibodies; Chapter 7: VEGF Trap; Ziv-Aflibercept (Zaltrap®); Chapter 8: Tyrosine Kinase Inhibitors; Angiogenesis Inhibitors and Multi-Kinase Inhibitors; Breakpoint Cluster Region-Abelson Murine Leukemia Viral Oncogene Homolog 1 (BCR-ABL) Inhibitors; B-Cell Receptor (BCR) Pathway Inhibitors; EGFR-Ras-Raf-MEK-ERK (MAPK) Pathway Inhibitors; Miscellaneous Oral Targeted Therapies</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="6">880-01</subfield><subfield code="a">Appendix A: Agents Requiring Renal and/or Hepatic Dose AdjustmentsAppendix B: Extravasation Risk of Chemotherapeutic Agents; Index</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Antineoplastic agents</subfield><subfield code="x">Physiological effect</subfield><subfield code="v">Problems, exercises, etc.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Tumors</subfield><subfield code="x">Chemotherapy</subfield><subfield code="v">Problems, exercises, etc.</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Antineoplastic Agents</subfield><subfield code="x">pharmacology</subfield><subfield code="0">https://id.nlm.nih.gov/mesh/D000970Q000494</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Neoplasms</subfield><subfield code="x">drug therapy</subfield><subfield code="0">https://id.nlm.nih.gov/mesh/D009369Q000188</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Anticancéreux</subfield><subfield code="x">Effets physiologiques</subfield><subfield code="v">Problèmes et exercices.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Tumeurs</subfield><subfield code="x">Chimiothérapie</subfield><subfield code="v">Problèmes et exercices.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL</subfield><subfield code="x">Pharmacology.</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Antineoplastic agents</subfield><subfield code="x">Physiological effect</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Tumors</subfield><subfield code="x">Chemotherapy</subfield><subfield code="2">fast</subfield></datafield><datafield tag="655" ind1=" " ind2="2"><subfield code="a">Examination Questions</subfield><subfield code="0">https://id.nlm.nih.gov/mesh/D020475</subfield></datafield><datafield tag="655" ind1=" " ind2="2"><subfield code="a">Problems and Exercises</subfield><subfield code="0">https://id.nlm.nih.gov/mesh/D020497</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="a">exercise books.</subfield><subfield code="2">aat</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="a">Problems and exercises</subfield><subfield code="2">fast</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="a">Problems and exercises.</subfield><subfield code="2">lcgft</subfield><subfield code="0">http://id.loc.gov/authorities/genreForms/gf2014026154</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="a">Problèmes et exercices.</subfield><subfield code="2">rvmgf</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Perissinotti, Anthony J.,</subfield><subfield code="e">author.</subfield><subfield code="0">http://id.loc.gov/authorities/names/n2015190361</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Marini, Bernard L.,</subfield><subfield code="e">author.</subfield><subfield code="0">http://id.loc.gov/authorities/names/n2015190362</subfield></datafield><datafield tag="758" ind1=" " ind2=" "><subfield code="i">has work:</subfield><subfield code="a">Cancer pharmacology and pharmacotherapy review (Text)</subfield><subfield code="1">https://id.oclc.org/worldcat/entity/E39PCGCPrkhPt7kvqgxrr7VJMq</subfield><subfield code="4">https://id.oclc.org/worldcat/ontology/hasWork</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Print version:</subfield><subfield code="a">Worden, Francis P., MD.</subfield><subfield code="t">Cancer Pharmacology and Pharmacotherapy Review : Study Guide for Oncology Boards and MOC Exams.</subfield><subfield code="d">: Springer Publishing Company, ©2016</subfield><subfield code="z">9781620700761</subfield><subfield code="w">(DLC) 2015045238</subfield><subfield code="w">(OCoLC)930576198</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="l">FWS01</subfield><subfield code="p">ZDB-4-EBA</subfield><subfield code="q">FWS_PDA_EBA</subfield><subfield code="u">https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=1193410</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="880" ind1="8" ind2=" "><subfield code="6">505-01/(S</subfield><subfield code="a">Chapter 9: Antiandrogen TherapiesChapter 10: Mammalian Target of Rapamycin (mTOR) Inhibitors; Chapter 11: Histone Deacetylase (HDAC) Inhibitors; Chapter 12: Hypomethylating Agents; Chapter 13: Proteasome Inhibitors; Chapter 14: Immunomodulatory Agents; Chapter 15: L-Asparaginase Enzymes; Chapter 16: Promyelocytic Leukemia Gene Retinoic Acid Receptor-Alpha (PML-RARα) Translocation Inhibitors; Part III: Miscellaneous Oncolytics; Chapter 17: Sipuleucel-T (Provenge®); Chapter 18: Omacetaxine (Synribo®); Chapter 19: Estramustine (Emcyt®)</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">EBSCOhost</subfield><subfield code="b">EBSC</subfield><subfield code="n">1193410</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">ProQuest MyiLibrary Digital eBook Collection</subfield><subfield code="b">IDEB</subfield><subfield code="n">cis34101607</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">YBP Library Services</subfield><subfield code="b">YANK</subfield><subfield code="n">12872620</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">Coutts Information Services</subfield><subfield code="b">COUT</subfield><subfield code="n">34101607</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">ProQuest Ebook Central</subfield><subfield code="b">EBLB</subfield><subfield code="n">EBL4428049</subfield></datafield><datafield tag="994" ind1=" " ind2=" "><subfield code="a">92</subfield><subfield code="b">GEBAY</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-4-EBA</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-863</subfield></datafield></record></collection> |
| genre | Examination Questions https://id.nlm.nih.gov/mesh/D020475 Problems and Exercises https://id.nlm.nih.gov/mesh/D020497 exercise books. aat Problems and exercises fast Problems and exercises. lcgft http://id.loc.gov/authorities/genreForms/gf2014026154 Problèmes et exercices. rvmgf |
| genre_facet | Examination Questions Problems and Exercises exercise books. Problems and exercises Problems and exercises. Problèmes et exercices. |
| id | ZDB-4-EBA-ocn942588609 |
| illustrated | Illustrated |
| indexdate | 2024-11-27T13:27:04Z |
| institution | BVB |
| isbn | 9781617052521 1617052523 162070076X 9781620700761 |
| language | English |
| oclc_num | 942588609 |
| open_access_boolean | |
| owner | MAIN DE-863 DE-BY-FWS |
| owner_facet | MAIN DE-863 DE-BY-FWS |
| physical | 1 online resource (xiv, 189 pages) : color illustrations |
| psigel | ZDB-4-EBA |
| publishDate | 2016 |
| publishDateSearch | 2016 |
| publishDateSort | 2016 |
| publisher | Demos Medical, |
| record_format | marc |
| spelling | Worden, Francis P., author. http://id.loc.gov/authorities/names/n2013181342 Cancer pharmacology and pharmacotherapy review : study guide for oncology boards and MOC exams / Francis P. Worden, Anthony J. Perissinotti, Bernard L. Marini. New York : Demos Medical, [2016] 1 online resource (xiv, 189 pages) : color illustrations text txt rdacontent computer c rdamedia online resource cr rdacarrier Online resource; title from PDF title page (EBSCO, viewed March 8, 2016). Includes index. Cancer Pharmacology and Pharmacotherapy Review is the first book devoted entirely to providing the 'must-know' facts on each cancer agent including their pharmacokinetics, FDA-approved indications, toxicity, interactions, and other important information that is commonly found on board examinations and essential for any clinician or practitioner to review . The authors, an oncologist and two pharmacists, have developed a handy question-and-answer format to present the material in digestible bursts. As the pharmacology section continues to represent a major portion of the medical oncology exam and a key component on oncology MOC exams, this portable study guide will help prepare anyone looking to fine-tune their knowledge on cancer drugs before the test. Not to mention, with recent advancements in the field of cancer treatment, it has become more cumbersome to recall and maintain essential knowledge of every cancer therapeuticómaking this book not only an exam resource but also a handy quick reference for oncologists and pharmacists alike. Key Features: Conveniently organized and arranged by drug class and subtypes for easier recall and classification Includes proper dosage adjustments to account for liver and kidney dysfunction. Features tables throughout that provide quick reference regarding FDA-approved medications Simplified diagrams and illustrations facilitate the pharmacokinetic processes. Cover; Title; Copyright; Contents; List of Figures; List of Tables; Preface; Share Cancer Pharmacology and Pharmacotherapy Review: Study Guide for Oncology Boards and MOC Exams; Part I: Traditional Chemotherapy; Chapter 1: Microtubule Inhibitors; Taxanes and Related Agents; Vinca Alkaloids; Chapter 2: Alkylating Agents; Nitrogen Mustards; Non-Nitrogen Mustards; Platinums; Antitumor Antibiotics; Chapter 3: Enzyme Inhibitors-Topoisomerase I Inhibitors; Camptothecans; Chapter 4: Enzyme Inhibitors-Topoisomerase II Inhibitors; Epipodophyllotoxins; Anthracyclines; Chapter 5: Antimetabolites AntifolatesPurine Antagonists; Purine Analogues; Pyrimidine Analogues/Fluoropyrimidines; Pyrimidine Analogues/Deoxycytidine Analogues; Part II: Next-Generation Antineoplastics; Chapter 6: Monoclonal Antibodies; Chapter 7: VEGF Trap; Ziv-Aflibercept (Zaltrap®); Chapter 8: Tyrosine Kinase Inhibitors; Angiogenesis Inhibitors and Multi-Kinase Inhibitors; Breakpoint Cluster Region-Abelson Murine Leukemia Viral Oncogene Homolog 1 (BCR-ABL) Inhibitors; B-Cell Receptor (BCR) Pathway Inhibitors; EGFR-Ras-Raf-MEK-ERK (MAPK) Pathway Inhibitors; Miscellaneous Oral Targeted Therapies 880-01 Appendix A: Agents Requiring Renal and/or Hepatic Dose AdjustmentsAppendix B: Extravasation Risk of Chemotherapeutic Agents; Index Antineoplastic agents Physiological effect Problems, exercises, etc. Tumors Chemotherapy Problems, exercises, etc. Antineoplastic Agents pharmacology https://id.nlm.nih.gov/mesh/D000970Q000494 Neoplasms drug therapy https://id.nlm.nih.gov/mesh/D009369Q000188 Anticancéreux Effets physiologiques Problèmes et exercices. Tumeurs Chimiothérapie Problèmes et exercices. MEDICAL Pharmacology. bisacsh Antineoplastic agents Physiological effect fast Tumors Chemotherapy fast Examination Questions https://id.nlm.nih.gov/mesh/D020475 Problems and Exercises https://id.nlm.nih.gov/mesh/D020497 exercise books. aat Problems and exercises fast Problems and exercises. lcgft http://id.loc.gov/authorities/genreForms/gf2014026154 Problèmes et exercices. rvmgf Perissinotti, Anthony J., author. http://id.loc.gov/authorities/names/n2015190361 Marini, Bernard L., author. http://id.loc.gov/authorities/names/n2015190362 has work: Cancer pharmacology and pharmacotherapy review (Text) https://id.oclc.org/worldcat/entity/E39PCGCPrkhPt7kvqgxrr7VJMq https://id.oclc.org/worldcat/ontology/hasWork Print version: Worden, Francis P., MD. Cancer Pharmacology and Pharmacotherapy Review : Study Guide for Oncology Boards and MOC Exams. : Springer Publishing Company, ©2016 9781620700761 (DLC) 2015045238 (OCoLC)930576198 FWS01 ZDB-4-EBA FWS_PDA_EBA https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=1193410 Volltext 505-01/(S Chapter 9: Antiandrogen TherapiesChapter 10: Mammalian Target of Rapamycin (mTOR) Inhibitors; Chapter 11: Histone Deacetylase (HDAC) Inhibitors; Chapter 12: Hypomethylating Agents; Chapter 13: Proteasome Inhibitors; Chapter 14: Immunomodulatory Agents; Chapter 15: L-Asparaginase Enzymes; Chapter 16: Promyelocytic Leukemia Gene Retinoic Acid Receptor-Alpha (PML-RARα) Translocation Inhibitors; Part III: Miscellaneous Oncolytics; Chapter 17: Sipuleucel-T (Provenge®); Chapter 18: Omacetaxine (Synribo®); Chapter 19: Estramustine (Emcyt®) |
| spellingShingle | Worden, Francis P. Perissinotti, Anthony J. Marini, Bernard L. Cancer pharmacology and pharmacotherapy review : study guide for oncology boards and MOC exams / Cover; Title; Copyright; Contents; List of Figures; List of Tables; Preface; Share Cancer Pharmacology and Pharmacotherapy Review: Study Guide for Oncology Boards and MOC Exams; Part I: Traditional Chemotherapy; Chapter 1: Microtubule Inhibitors; Taxanes and Related Agents; Vinca Alkaloids; Chapter 2: Alkylating Agents; Nitrogen Mustards; Non-Nitrogen Mustards; Platinums; Antitumor Antibiotics; Chapter 3: Enzyme Inhibitors-Topoisomerase I Inhibitors; Camptothecans; Chapter 4: Enzyme Inhibitors-Topoisomerase II Inhibitors; Epipodophyllotoxins; Anthracyclines; Chapter 5: Antimetabolites AntifolatesPurine Antagonists; Purine Analogues; Pyrimidine Analogues/Fluoropyrimidines; Pyrimidine Analogues/Deoxycytidine Analogues; Part II: Next-Generation Antineoplastics; Chapter 6: Monoclonal Antibodies; Chapter 7: VEGF Trap; Ziv-Aflibercept (Zaltrap®); Chapter 8: Tyrosine Kinase Inhibitors; Angiogenesis Inhibitors and Multi-Kinase Inhibitors; Breakpoint Cluster Region-Abelson Murine Leukemia Viral Oncogene Homolog 1 (BCR-ABL) Inhibitors; B-Cell Receptor (BCR) Pathway Inhibitors; EGFR-Ras-Raf-MEK-ERK (MAPK) Pathway Inhibitors; Miscellaneous Oral Targeted Therapies Appendix A: Agents Requiring Renal and/or Hepatic Dose AdjustmentsAppendix B: Extravasation Risk of Chemotherapeutic Agents; Index Antineoplastic agents Physiological effect Problems, exercises, etc. Tumors Chemotherapy Problems, exercises, etc. Antineoplastic Agents pharmacology https://id.nlm.nih.gov/mesh/D000970Q000494 Neoplasms drug therapy https://id.nlm.nih.gov/mesh/D009369Q000188 Anticancéreux Effets physiologiques Problèmes et exercices. Tumeurs Chimiothérapie Problèmes et exercices. MEDICAL Pharmacology. bisacsh Antineoplastic agents Physiological effect fast Tumors Chemotherapy fast |
| subject_GND | https://id.nlm.nih.gov/mesh/D000970Q000494 https://id.nlm.nih.gov/mesh/D009369Q000188 https://id.nlm.nih.gov/mesh/D020475 https://id.nlm.nih.gov/mesh/D020497 http://id.loc.gov/authorities/genreForms/gf2014026154 |
| title | Cancer pharmacology and pharmacotherapy review : study guide for oncology boards and MOC exams / |
| title_auth | Cancer pharmacology and pharmacotherapy review : study guide for oncology boards and MOC exams / |
| title_exact_search | Cancer pharmacology and pharmacotherapy review : study guide for oncology boards and MOC exams / |
| title_full | Cancer pharmacology and pharmacotherapy review : study guide for oncology boards and MOC exams / Francis P. Worden, Anthony J. Perissinotti, Bernard L. Marini. |
| title_fullStr | Cancer pharmacology and pharmacotherapy review : study guide for oncology boards and MOC exams / Francis P. Worden, Anthony J. Perissinotti, Bernard L. Marini. |
| title_full_unstemmed | Cancer pharmacology and pharmacotherapy review : study guide for oncology boards and MOC exams / Francis P. Worden, Anthony J. Perissinotti, Bernard L. Marini. |
| title_short | Cancer pharmacology and pharmacotherapy review : |
| title_sort | cancer pharmacology and pharmacotherapy review study guide for oncology boards and moc exams |
| title_sub | study guide for oncology boards and MOC exams / |
| topic | Antineoplastic agents Physiological effect Problems, exercises, etc. Tumors Chemotherapy Problems, exercises, etc. Antineoplastic Agents pharmacology https://id.nlm.nih.gov/mesh/D000970Q000494 Neoplasms drug therapy https://id.nlm.nih.gov/mesh/D009369Q000188 Anticancéreux Effets physiologiques Problèmes et exercices. Tumeurs Chimiothérapie Problèmes et exercices. MEDICAL Pharmacology. bisacsh Antineoplastic agents Physiological effect fast Tumors Chemotherapy fast |
| topic_facet | Antineoplastic agents Physiological effect Problems, exercises, etc. Tumors Chemotherapy Problems, exercises, etc. Antineoplastic Agents pharmacology Neoplasms drug therapy Anticancéreux Effets physiologiques Problèmes et exercices. Tumeurs Chimiothérapie Problèmes et exercices. MEDICAL Pharmacology. Antineoplastic agents Physiological effect Tumors Chemotherapy Examination Questions Problems and Exercises exercise books. Problems and exercises Problems and exercises. Problèmes et exercices. |
| url | https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=1193410 |
| work_keys_str_mv | AT wordenfrancisp cancerpharmacologyandpharmacotherapyreviewstudyguideforoncologyboardsandmocexams AT perissinottianthonyj cancerpharmacologyandpharmacotherapyreviewstudyguideforoncologyboardsandmocexams AT marinibernardl cancerpharmacologyandpharmacotherapyreviewstudyguideforoncologyboardsandmocexams |